Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Konteatis, Z., Artin, E., Nicolay, B., Straley, K., Padyana, A.K., Jin, L., Chen, Y., Narayaraswamy, R., Tong, S., Wang, F., Zhou, D., Cui, D., Cai, Z., Luo, Z., Fang, C., Tang, H., Lv, X., Nagaraja, R., Yang, H., Su, S.M., Sui, Z., Dang, L., Yen, K., Popovici-Muller, J., Codega, P., Campos, C., Mellinghoff, I.K., Biller, S.A.(2020) ACS Med Chem Lett 11: 101-107
- PubMed: 32071674 
- DOI: 10.1021/acsmedchemlett.9b00509
- Primary Citation of Related Structures:  
6VEI, 6VFZ, 6VG0 - PubMed Abstract: 
Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite d-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH m ...